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The 28th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held November 8–10, 2013 in
National Harbor MD, and was organized by Paolo Ascierto (Instituto Nazionale Tumori – Fondazione ‘G. Pascale’),
David Munn (Georgia Regent’s University), A. Karolina Palucka (Baylor Institute for Immunology Research) and Paul
Sondel (University of Wisconsin). This meeting included over 1100 registered participants from 32 separate
countries, making it the largest SITC meeting held to date. It highlighted significant worldwide progress in the
development and application of cancer immunology to the practice of clinical oncology, including advances in
diagnosis, prognosis and therapy, utilizing a variety of immunological pathways and mechanisms for a variety of
oncologic conditions. Presentations and posters demonstrated that many concepts that had been pursued
preclinically in the past are now being translated into clinical practice, with clear benefits for patients. One month
after this 28th annual meeting, the Journal Science selected the field of Cancer Immunotherapy as the overall #1
scientific “breakthrough” for 2013.
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For over a century, immunology researchers have specu-
lated that the immune mechanisms that are able to provide
protection from pathogens, destroy transplanted allogeneic
organs, or cause tissue destruction in the form of auto-
immune disorders, might be directed selectively against
cancer in the form of cancer immunotherapy. While basic
research has, for over 60 years, demonstrated the potential
for such mechanisms in vitro and in mice, the effective
translation into clinical practice has been slower. In 1984,
the Society for Immunotherapy of Cancer was established.
Its mission is “to improve cancer patient outcomes by ad-
vancing the science, development and application of cancer
immunology and immunotherapy through our core values
of interaction/integration, innovation, translation and lead-
ership in the field.” Since then, effective clinical application
of immunotherapeutic principles to clinical oncology has* Correspondence: pmsondel@humonc.wisc.edu
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unless otherwise stated.grown progressively. In 2013, cancer immunotherapy was
selected as overall the top field with scientific breakthrough
[1]. This year’s SITC meeting included a diverse array of
effective applications of immune principles into clinical
practice, with beneficial impact in the management of
many distinct cancers affecting children and adults.
Review
Keynote presentations
Highlighting this meeting were 2 outstanding keynote
presentations regarding cutting- edge strategies that are
demonstrating the impact of both innate and T-cell me-
diated immune effector mechanisms.
Keynote presentation by Giorgio Trinchieri (NCI)
Humans are a composite of different species including
bacterial, fungi, viruses.
Microbial cells outnumber human cells by 10 fold, at
genome level in the gut 99% of genome comes from
commensal microbiota. How the inflammatory environ-
ment in the host affects immunotherapy and how com-
mensal microbiota affects the response to therapy and tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lated by skin microbiota [2]. However, gut commensals
have systemic effects and regulate systemic immunity
and inflammatory tone.
It is now well documented that inflammation con-
tributes to the development, progression, and treatment of
cancer. However, the mechanisms are not yet resolved. It
also remains unclear whether commensal bacteria affect in-
flammation in the sterile tumor microenvironment. Giorgio
Trinchieri discussed studies in transplantable murine tumor
models that were focused on addressing this issue [3].
It has been found that disruption of the microbiota im-
pairs the response of subcutaneous tumors to CpG-
oligonucleotide immunotherapy. Similar effects were
observed with oxiplatinum or cisplatinum. Oxiplatin but
not cisplatin induces immunogenic cell death. These anti-
tumor effects are dependent on the presence of microbiota,
even in the absence of immunogenic cell death, suggesting
that the immune component may rely on early innate
effects rather than adaptive immunity. Mechanistically,
in antibiotic-treated or germ-free mice, tumor-infiltrating
myeloid-derived cells responded poorly to therapy, result-
ing in lower cytokine production and tumor necrosis after
CpG-oligonucleotide treatment and deficient production
of reactive oxygen species and cytotoxicity after chemo-
therapy. Thus, optimal responses to cancer therapy re-
quire an intact commensal microbiota that mediates its
effects by modulating myeloid-derived cell functions in
the tumor microenvironment [3]. More importantly, the
composition of fecal microbiota could be used to segre-
gate mice with high and low intratumoral TNF. This in
turn might enable patient stratification in future studies.
Keynote presentation by Carl H. June, recipient of The
Richard V. Smalley MD 2013 Award
Since 2005, SITC honors a luminary in the field who has
significantly contributed to the advancement of cancer
immunotherapy research by presenting the annual Richard
V. Smalley MD Memorial Award, which is associated with
the Smalley keynote lecture at the Annual SITC meeting.
The awardee this year Carl H. June of the University of
Pennsylvania, has led innovative translational research for
over 25 years, with the most recent focus being the devel-
opment of the Chimeric Antigen Receptor modified T-cell
(CART) approach. Carl June summarized how the past
15 years of progress have expanded upon the original
concept presented by Zelig Eshhar [4], in which variable
regions of tumor-reactive monoclonal antibodies (mAbs)
(VH and VL) are linked to transmembrane and signaling
domains of T cell activating molecules to create membrane
based receptors with specificity for the tumor antigen rec-
ognized by the original mAb [4]. These receptors can be
transfected into T cells, for example with lentiviruses. Pre-
clinical work demonstrated how CD3-ζ and 41BB signalingcomponents enhanced proliferation and survival of T cells
in hypoxic conditions. The initial clinical work has been
done with CART reactive to CD-19 on malignant B cells,
with progress particularly in chronic lymphocytic leukemia
(CLL) in adults and acute lymphoblastic leukemia (ALL) in
children [5,6]. As of the SITC meeting, CarlJune’s team
had treated 35 patients with CLL and 20 with ALL. Of the
20 with ALL, ½ had relapsed after allogeneic BMT. Of
these 20 children, 17 were in complete remission, and with
persistent B cell aplasia; documenting the persistent effects
of the CART cells. Toxicities included the persistent B cell
aplasia and profound tumor lysis and cytokine storm, seen
1–2 weeks into the treatment for ALL. This cytokine storm
has been ameliorated by using anti-IL6 mAb. The B cell
aplasia, while undesired, is acceptable, as patients can re-
ceive passive replacement of IgG, thus making their B cells
“expendable”. These CART cells can traffic into the CNS.
In ALL patients, it appears that each individual CART cell
(or its progeny) can destroy 1000 tumor cells. Ongoing
efforts in CarlJune’s program, and at other centers, are now
moving into analyses of CART reactive with other tumor
targets, by using mAbs that recognize antigens expressed
on other tumors. Among these are EGFR on glioblastoma,
PSMA on prostate cancer, mesothelin on ovarian cancer,
HER2 on breast (and other) cancers, and several other tar-
gets. Because some of these targets are also expressed on
normal tissues that are “not expendable”, novel approaches
are being developed to decrease the potency or longevity
of the CART effect, to decrease potential toxicity. This in-
cludes generating “short lived” CART cells by inducing
CAR expression with short-lived RNA, rather than trans-
fecting with a DNA construct that remains permanently.
A major question raised for this very exciting technology
is the feasibility of wide-scale application. If the efficacy
warrants it, wider clinical application should follow. As an
example, allogeneic BMT was done at only a handful of
centers in the late 1970s; over the past 3 decades hundreds
of centers have adopted this complex, yet effective ap-
proach, and now over a million BMTs have been performed
worldwide. Carl June suggests that high-tech approaches
towards cost-effective robotics and automation may be-
come key in enabling the CART approach in order to be
expanded broadly and to enable its future application at
many sites for large population of patients with cancers that
may potentially benefit from this potent immunotherapy.
Overview of sessions
The 2013 Annual Meeting brought together several
broad themes that are timely and relevant for clinical and
translational immunotherapy. One theme was activating
immunotherapy by administration of either anti-tumor
effector cells, antibodies or vaccines. Presentations in this
area included sessions on cellular therapeutics (“Adoptive
Immunotherapy” session, and the Richard V. Smalley
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(“Antibody Recognition to Engage Cells of the Innate and
Adaptive Immune Systems”). A second broad theme within
the meeting was tumor-induced negative regulation in the
immune system. This was addressed in sessions on “Tumor
Immune Resistance and Overcoming It”, “Tumor Micro-
environment and Innate Cells Recognition” and a session
on the immunoregulatory aspects of “Metabolism and
Immunity”. In recognition of the progress that has been
bringing individual agents to the clinic, a Plenary Session
was devoted to “Combination Approach in Cancer”. Bio-
marker analysis is becoming increasingly important – both
in identifying patients most likely to benefit from therapy,
and as markers of response. Sessions were included on
“Biomarkers and Immunoscoring” and a Hot-Topic sympo-
sium on “Predictive biomarkers in Checkpoint Blockade”.
Finally, sessions were provided for the update on the de-
velopment of the Immunoscore, on the Cancer Immuno-
therapy Trials Network (CITN), and by representatives
from the NCI and the FDA.
Tumor microenvironment and innate cells recognition
Preclinical studies have revealed an unexpected ability of
immune system to contribute to the success of chemother-
apy and radiotherapy. Anticancer therapies can trigger im-
mune system activation by promoting the release of danger
signals from dying tumor cells and/or the elimination of
immunosuppressive cells. Two talks discussed the role of
myeloid cells in response to chemotherapy. Lionel Apetoh’s
(INSERM, France) group has recently discovered however
that some chemotherapies, such as 5-fluorouracil (5FU)
and gemcitabine, exert conflicting effects on anticancer im-
mune responses. Although 5-fluorouracil and Gemcitabine
(GEM) selectively eliminated myeloid-derived suppressive
cells in tumor-bearing rodents, these chemotherapies pro-
moted the release of IL-1β and the development of pro-
angiogenic IL-17-producing CD4 T cells [7]. Indeed, GEM
and 5FU triggers inflammasome in MDSCs and caspase 1
activation in vitro and in vivo leading to IL1β release. The
protumor effect of IL1β is via action on the host rather than
tumor via impact on CD4+ T cell differentiation and IL17
production driven by MDSCs. Importantly, in a pilot clin-
ical study, two patients with metastatic colorectal cancer
received anakinra resulting in reversal of 5FU resistance.
Masahisa Jinushi (Hokkaido University) discussed work
centered on factors that modulate DAMP-mediated in-
nate immune response. TIM-3 and TIM4 were identi-
fied in siRNA-based screen as upregulated in DCs. High
TIM-3 expression in tumor associated DCs can be driven
by VEGFA and IL10. TIM-3 has multiple effects including
suppression of nucleic acid mediated-innate immunity
via inhibition of nucleic acid based recognition and type
I interferon production. TIM-3 binds HMGB1 and re-
presses endocytosis of nucleic acids in endosomes andmoreover DC specific production of TIM3 attenuates
anti-tumor effects of chemotherapy [8]. TIM4 promotes
lysosmal degradation of tumor antigens in macrophages.
TIM4 activates autophagy via interaction with AMPK-α1
after ingestion of apoptotic tumor cells. TIM4 macrophages
activated via chemotherapy degrade tumor associated anti-
gens via authophagy and inhibit CD8+ T cells.
Innate immune mechanisms in the tumor microenvir-
onment were further discussed in the talk from Thomas
Gajewski’s lab (Univeristy of Chicago). There, Xanthenone
derivative DMXAA induces STING-dependent and IFNα-
mediated effects on DCs. This in turn enables inhibition
of melanoma via immune effects and induction of mem-
ory demonstrated by mice resistance to tumor challenge.
As discussed by Anu Wallecha (Advaxis Inc), administra-
tion of Listeria-based vaccine leads to induction of high
avidity CTLs in a mouse model of prostate cancer. This
was associated with reduction of Tregs and IL-10 pro-
duction in tumors. Also, MDSCs were affected, both
monocytic and granulocytic populations, and their sup-
pressive activity was reduced via lower arginase Ievels in
this setting.
Tumor microenvironments are complex and myeloid
cells are not the only players. Indeed, Peter Nelson (Fred
Hutchinson Cancer Research Center) discussed modu-
lating tumor microenvironment responses to genotoxic
cancer therapy and impact on fibroblasts via the DNA
damage associated secretory response program. These
results originated in clinical observations in prostate can-
cer where 54 patients received prior to surgery 4 cycles
mitoxantrone-docetaxel, therapy. No complete clinical re-
sponses in tumors were observed even though the DNA
damage in cells and stroma could be detected. This is a
DNA damage associated secretory program which in-
cludes IL6, IL8, and IL33 secretion among others. Similar
patterns can be found in breast and ovarian after geno-
toxic therapy. Molecular analysis revealed alteration of
WNT16B in the TME in about 50% of patients. Mechanis-
tically, β-catenin targets genes associated with WNT16B
post chemo and fibroblasts promote tumor growth via
paracrine activation of WNTB16 via NFkB. Clinically, pa-
tients without WNT16B induction post chemo had better
overall survival.
Lisa Coussens (Oregon Health & Science University)
summed up the session by discussing the leukocyte
complexity in human breast cancer. Clinical observa-
tions showed that tumor microenvironments dominated
by CD68+ and low CD8+ cells (CD68 high/CD8 low
phenotype) show poor progression free survival and over-
all survival across breast cancer subtypes [9]. In a murine
model of breast cancer, CSF1/CSF1R blockade leads to a
drop in macrophages in primary tumor and an increase
in CD8 T cell infiltrate. Macrophage depletion combined
with Taxol therapy results in much improved responses in
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sis. Mechanistically, arginase and IL-10 derived from po-
larized macrophages are inhibited, thereby releasing the
brakes on CD8+ T cells. Accordingly, IL-10R blockade re-
sults in the inhibition of tumor progression and improved
survival in mice which is CD8 T cell dependent, is associ-
ated with increased DCs infiltrate and involves IL-12.
Antibody recognition to engage cells of the innate and
adaptive immune systems (antibody dependent
cell-mediated cytotoxicity: ADCC)
Certain mAbs and their derivatives can enable tumor-
selective recognition by their specific interactions with
molecules expressed on tumor cell surfaces. Therapeu
tically-focused interventions directed to activate immune
effector cells, engineer changes in the mAbs, and create
fusion proteins of the mAbs and agents that activate ef-
fector cells are being developed and used pre-clinically
and clinically. The goal is to enable diverse effector cells
within the patient that might not otherwise be able to
selectively recognize their cancer to become activated
and focus their immunologic activities on mediating ef-
fective direct or indirect anti-tumor responses.
Raphael Clynes (Columbia University) presented his
continuing work on immune activation by antitumor anti-
bodies. In pre-clinical mouse models, his group has dem-
onstrated that effective Fc receptors are involved in at
least 2 pathways in the beneficial antitumor effects medi-
ated by tumor reactive mAbs. First, FcRs are essential
components in ADCC mediated by cells of the innate
immune system, including ADCC by NK cells as well as
monocytoid and myeloid elements (Macrophages and
neutrophils). Secondly, in immunologically intact animals,
FcRs also play a role in enabling uptake of antigen into
dendritic cells and effective presentation of them to drive
an adaptive immune response. These adaptive responses,
driven by tumor reactive antibody, can be further enhanced
by elimination of Treg cells. Clinical data in patients re-
ceiving mAb therapy for HER2+ breast cancer confirm
induction of an adaptive immune response following
Trastuzumab therapy, with serological evidence of adap-
tive immune responses to additional antigens, other than
HER2, on the patients’ cancer [10].
Ron Levy (Stanford University) showed pre-clinical and
clinical data demonstrating that the efficacy of tumor-
reactive mAbs can be enhanced by co-administration of a
second mAb (anti-CD137, that recognizes 41BB) that fur-
ther stimulates activated NK cells. Once NK cells are acti-
vated (such as via activation through their FcR in the
process of initiating ADCC), they upregulate their CD137
expression. At that point, interaction with an agonistic
anti-CD137 mAb can further activate the NK cell, result-
ing in substantial augmentation of ADCC. In vitro studies
led to elegant pre-clinical models in immunodeficient micebearing human lymphoma or breast cancer xenografts.
Treatment efficacy with antitumor mAb and human NK
cells was substantially augmented when anti-CD137 mAb
was co-administered [11]. Ongoing clinical testing of this
concept has shown initial exciting results. Some patients
that have recurrent lymphoma following Rituximab ther-
apy are showing prolonged responses following combined
treatment with Rituximab and anti-CD137. Ron Levy also
provided intriguing results looking at beneficial effects of
locally injected (i.e., intratumoral) anti-CTLA4 with CpG
and anti-OX-40, providing very potent pre-clinical efficacy,
with systemic antitumor effects [12]. This suggests that
one might “inject locally and treat globally”.
Gabrielle Romain (University of Houston) and colleagues
have developed a single cell high-throughput microscopy
assay for measuring ADCC by anti-CD33 mAbs. Using this
approach they have shown that a genetically engineered
anti-CD33 mAb (with an Fc-end improved for ADCC)
enables more NK cells to mediate ADCC, speeds up the
kinetics of conjugation and enables target cell apoptosis
with fewer cell-cell contacts.
Beatrix Kotlan (National Institute of Oncology, Budapest,
Hungary) and colleagues have been dissecting the specifi-
city of antibodies made by B cells within tumors from 87
patients with melanoma using a sequencing approach of
IgG light and heavy chains. Several of these melanoma
patients were shown to express a unique GD3 sialated
glycoprotein.
Pablo Umana (Roche Glycart AG) described the develop-
ment and activity of the recently FDA-approved anti-CD20
mAb Gazyva (Obinutuzumab). This is the first drug with
“breakthrough therapy designation”, and first Fc engineered
mAb, to be approved by the FDA. It reacts against an epi-
tope on CD20 that can cause direct mAb-mediated cell
death of CD20+ tumor cells, as well as inducing ADCC.
Furthermore, the defucosylated Fc end of the mAb enables
better interactions with FcRs and enhanced ADCC [13]. In
clinical testing, when combined with chlorambucil in the
treatment of CLL, Gazyva showed a longer time to progres-
sion (26.7 mo. vs. 15.2 mo). Additionally, using genetically
engineered mAbs and immunocytokines are in develop-
ment and testing.
Paul Sondel (University of Wisconsin) summarized pre-
clinical and clinical testing of anti-GD2 mAb for neuro-
blastoma. An approach tested by the Children’s Oncology
Group showed that a combination of the chimeric anti-
GD2 mAb (ch14.18) plus IL2 and GM-CSF to boost
ADCC, yielded an increase in event free survival over no
immunotherapy (66% vs. 46% at 2 years) [14]. Further de-
velopment includes testing of the humanized form of this
mAb linked to IL-2 (the hu14.18-IL2 immunocytokine).
Clinical activity was seen in Phase II testing. Furthermore,
the involvement of NK cells in the clinical effect is
supported by analyses of Killer Immunoglobulin-like
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likelihood of response in patients that have favorable
KIR/KIR-Ligand genotypes [15].
Adoptive immunotherapy
Ex vivo technology is providing the capability to expand,
select, and modify varying immune cell types to yield large
numbers of antigen specific (tumor specific) cells that can
be infused as clinical anti-tumor therapy. Different meth-
odologies are utilizing recognition capabilities of T cells
that are derived from their own TCR repertoire versus
conferring specificity by providing them with genetically
modified receptors, based on TCR recognition, mAb rec-
ognition, or other ligand-specific receptors. While T cells
have been primarily utilized in these trials, these manipu-
lations are also relevant to NK cells, which are also being
evaluated. Presentations at SITC focused on the rationale,
distinctions and capabilities of these different forms of
adoptive cellular immunotherapy and on what clinical set-
tings are showing clinical benefit. This important area of
research has made much progress over the past year, as
highlighted at this year’s meeting by the Richard Smalley
Award, going to Carl June, for his and his team’s work in
pre-clinical and clinical development of chimeric antigen
receptor modified T cells (CART) for adoptive immuno-
therapy (see summary of his lecture, above).
Dirk Busch (Technical University of Munich) and col-
leagues are investigating the properties of stem cells that
can reconstitute immune function. They have shown that
the subpopulation of cells that initially respond in a murine
immune response are not necessarily the same as those
that will expand with the recall response. The ones able to
respond upon recall are CD62high. They can take a single
naïve CD62high T cell, and reconstitute an immunodeficient
RAG−/− mouse with it, and then go through 3 repeat trans-
fers from one RAG−/− recipient to another, each demon-
strating successful reconstitution. This demonstrates that
central memory T cells (TCM) are true “adult tissue stem
cells”, with high regenerative power, and this also makes
them good candidates for use with genetically engineered
receptors (CARs or TCRs) for cancer therapies.
Stan Riddell (Fred Hutchinson Cancer Research Center)
and colleagues have been investigating adoptive immuno-
therapy pre-clinically and clinically. In adoptive transfer
studies in mice they see anti-tumor effects of genetically
engineered effector memory T cells (TEM) and central
memory T cells (TCM). However only the TCM were long-
lived in vivo and resulted in cures. They also found syn-
ergy between CD4 and CD8 TCM in their mouse model.
CART cells that were purified CD4 or CD8 were not as ef-
fective as a population that was mixed to contain CD4
and CD8 cells. Based on this, they are testing this com-
bined CD4 + CD8 CART approach clinically [16]. A recent
patient that responded to this approach has shown on day10 after CART therapy that 64% of circulating T cells are
CART-modified.
Anastasia Papadopoulou (Baylor College of Medicine)
and colleagues are taking a novel approach towards treat-
ing viral infection after HSCT. PBMCs from the HSCT
donor are stimulated in vitro with overlapping peptides for
ADV, EBV, CMV, BK and HHV6 viruses and cultured/
expanded with IL4/7 in vitro for 10 days. They routinely
get cell lines with potent anti-viral specificity but no
alloreactivity, based on in vitro testing [17]. So far, 11 pa-
tients were treated with these donor-derived anti-viral T
cell lines. Shortly after the infusions, the viremia is seen to
dramatically decrease, while anti-viral T-cell reactivity from
donor derived T cells increases (in PBMCs). Some patients
have shown complete clearance of detectible virus.
Hiroaki Ikeda (Mie University, Japan) and colleagues
have chosen to focus on esophageal cancer, a very difficult
clinical setting. They have used genetically engineered T
cells that express TCRs that recognize HLA-A2404 re-
stricted MAGE-A4, found in high density on esophageal
cancer [18]. These T cells mediate potent killing against
cell lines in vitro. In adoptive transfer studies in xenograft
bearing mice, they can also mediate strong anti-tumor
effects. Clinical testing of this approach is underway in a
multi-institutional trial. In analyses of initial patients, it
is possible to detect these TCR-engineered T cells circu-
lating for many months. These TCR-engineered cells
can be removed from the patients PBMCs after therapy,
and continue to demonstrate in vitro killing of MAGE-
A4 bearing tumor cells.
Tumor immune resistance and overcoming It
Tumors create a local milieu that is highly immunosup-
pressive. This reflects multiple mechanisms, some known
and some still unclear. In addition to immunosuppressive
cytokines such as TGFβ, some tumors show extensive up-
regulation of immunoregulatory molecules such as PD-L1
on tumor cells, or on tumor-associated stromal cells such
as DCs. Another resistance mechanism is recruitment of
suppressive immune cells such as Tregs and MDSCs into
the tumor milieu. In addition to their local effects in the
tumor microenvironment, Tregs and MDSCs can also cre-
ate suppressive effects systemically, at sites such as spleen
and tumor-draining lymph nodes. These inhibitory path-
ways are becoming increasingly viable targets for therapy.
However, our mechanistic understanding of how tumors
create local and systemic immune suppression is still at
an early stage, and much discovery research remains to
be done. It is exciting for the field, however, that these
pathways have now become an active target for clinical
therapy.
Stephen Hodi (Dana Farber Cancer Institute) spoke on
clinical development of PD-1/PD-L1 blockade. He reviewed
the history of selected agents in the clinic, starting with
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58), which showed 18-28% response rates in Phase I, de-
pending on the tumor type. This included a number of
long-lasting responses, and also examples of late responses
(off study drug) suggestive of an ongoing immune reaction
against the tumor. In that study, expression of PD-L1 in
the tumor by immunohistochemistry was associated with
higher response rate. Additional agents were reviewed, in-
cluding MK-3475 (Merck) and MPDL3280A (anti-PD-L1,
Genentech/Roche), where an association of PD-L1 expres-
sion with response rate was again observed. Results of the
first combination trial of nivolumab with anti-CTLA-4
(ipilimumab) were recently reported, suggesting enhanced
activity of the combination. Future questions for investi-
gation were discussed, including whether synergy can
be obtained by simultaneously blocking more than one
checkpoint; and which preclinical animal models can best
predict clinical outcome of such interventions (a relevant
point since PD-1/PD-L1 blockade has worked better in
the clinic than might have been predicted from mouse
studies).
Holbrook Kohrt (Stanford Cancer Institute) presented
an abstract describing biomarkers of response to MPDL
3280A, an engineered antibody directed against PD-L1
(Genentech/Roche). Results were from a Phase I trial of
277 patients with solid tumors. Response rate was 14-
30% depending on tumor type, and patients with PD-L1
expression in the tumor at baseline had a higher rate of
response. Baseline expression of PD-L1 was associated
with increased infiltration of CD8+ cells and higher ex-
pression of IFN-γ in the tumor. There were 26 patients
with matched on-treatment biopsies available. Respond-
ing tumors showed increased CD8+ and Th1 responses
over baseline, and a concomitant increase in PD-L1 ex-
pression; whereas non-responders showed little inflam-
matory response in the tumor. These findings suggested
that the baseline level of spontaneous T cell immune re-
sponse against the tumor might be driving counter-
regulatory PD-L1 expression, and also became able to
drive the response to therapy when PD-L1 was blocked.
Rahul Roychoudhuri (National Cancer Institute) de-
scribed the role of the transcription factor BACH2 in
differentiation and function of Tregs and effector CD4
cells. Clinically, abnormalities of BACH2 have been associ-
ated with multiple forms of autoimmunity. Mice lacking
BACH2 had defective differentiation of Tregs, which was
due to the inability to repress competing pro-inflammatory
differentiation programs in the CD4 lineage. Thus, BACH2
is centrally positioned at the choice between tolerance/
Tregs versus inflammation/effector differentiation.
Dmitry Gabrilovich (Wistar Institute) spoke on the fate
of myeloid-derived suppressor cells in tumor-bearing
hosts. Granulocytic MDSCs progressively increase in the
presence of tumors and it has been assumed that theymust therefore have improved survival compared to nor-
mal granulocytes. In reality, however, granulocytic MDSCs
were found to have shortened survival and increased sen-
sitivity to apoptosis. Apoptosis appeared to be mediated
via the DR5 receptor and caspase 8. Engagement of DR5
in mouse models eliminated MDSCs and enhanced anti-
tumor immunotherapy. Human MDSCs likewise appeared
more sensitive to apoptosis via TRAIL/DR ligation. Thus,
MDSCs may be selectively sensitive to elimination by
TRAIL administration.
Vaccines
The molecular identification of human cancer-specific
antigens has allowed the development of antigen-specific
immunotherapy. In one approach, autologous antigen-
specific T cells are expanded ex vivo and then re-infused
into patients. Another approach is through vaccination;
that is, the provision of an antigen together with an ad-
juvant to elicit therapeutic T cells in vivo. This session
discussed cutting edge approaches to cancer vaccines as
well as challenges that remain in efforts to generate ef-
fective therapeutic immunity.
Howard Kaufman (Rush University) discussed a phase
III study testing the clinical activity of GM-CSF encoding
Herpes virus based vector (OPTIM Oncovex) in stage
IIIb-IV melanoma. By localizing GM-CSF to tumor sites
using this approach, the goal is to enable the in situ tumor
to function as an endogenous cancer vaccine. The control
arm received treatment with GM-CSF only. There was
2.1% vs 16.3% durable response rate in the control vs.
the Oncovex arm, with complete response 0.7% vs 10%.
36 month survival was 40.6% for Oncovex vs 27.8% for
the control arm. These are very encouraging data and
hopefully the next step will be combination therapy with
checkpoint inhibitors. Another approach to viral vectors
was discussed by Dr. Schlom who summarized emer-
ging concepts in vaccine therapy and focused on studies
with tumor antigen encoding viral vectors, specifically
TRICOM. The PROSTVAC phase II and phase III trial
in metastatic prostate cancer showed changes in tumor
growth kinetics, resulting in improved overall survival.
PANVAC is being tested in metastatic colorectal cancer
post surgery. Here as well, some benefit for overall survival
(but not DFS) was observed when comparing PANVAC vs
standard of care in a single center trial.
Cornelis Melief (Leiden University) discussed outcomes
of vaccination with long peptides combined with adjuvants
such as CpG or polyIC. In pre-malignant lesions, HPV tar-
geted vaccination led to very promising results with good
tumor control, which was dependent on CD8+ T cell
immunity. However, the efficacy of this vaccination proto-
col was much diminished in patients with established
HPV + cancer. Interestingly, vaccination during the mye-
loid nadir following cis-paltinum improved the outcome.
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of adaptive immunity in response to vaccination. These
very interesting results further support the rationale for
combination of immunotherapy with classical treatments
in oncology. The discussion of other approaches to en-
hance immunogenicity included a novel class of adjuvants
(Thomas Dubensky, Aduro BioTech) which are based on
cyclic di nucleotides able to activate STING; and the role
of IL18 which, when secreted from activated NK cells in
the presence of IFN alpha, primes DCs for CCL19 secre-
tion (Pawel Kalinski, University of Pittsburgh). This prim-
ing of DCs has been observed in mice and also in tumor
draining lymph nodes from patients with colorectal cancer.
Thus, IL18 acts as bridge between tumor and lymph nodes.
Finally, two presentations focused on challenges to the
creation of effective cancer vaccines. Vincent Brichard
(GSK) discussed GSK vaccines based on MAGE-3 tumor
antigen administered in combination with three adju-
vants (AS15) in liposomal formulation. Following posi-
tive phase II studies, phase III trials have been developed
in lung cancer (MAGRIT) and in melanoma (DERMA)
post surgery. The DERMA trial enrolled 1320 patients
with two primary endpoints: a) disease free survival in the
total population; and b) disease free survival in MAGE3A+
tumors. The study did not meet the goal for the 1st end-
point but will continue to assess data for the 2nd endpoint
in 2015. A critical point is selection of patients for active
immunotherapy; GSK has established a gene signature that
is being prospectively validated. Nicholas Restifo (NCI)
further underscored the need for patient stratification
and outlined three requirements for successful vaccines
including: 1. Choice of target antigen; 2. Matching T cells
with targets: 3. potent T cell repertoire; and 4. Control of
Tumor microenvironment.
Metabolism and immunity
In recent years, the role of metabolic pathways in regu-
lating both tumor biology and immune responses has
gained increasing attention. It has long been recognized
that tumors show multiple metabolic abnormalities, in-
cluding increased dependence on glycolysis (Warburg
effect), adaptation to hypoxia, and other changes. In the
immune system, factors such as cellular energy balance,
nutrient availability, hypoxia and redox state are more
than just “housekeeping” functions, they can also be critical
determinants of immune-cell activation, differentiation and
effector function. Metabolic sensing and control pathways
such as mTOR, GCN2 and HIF-1α are thus emerging as
potential therapeutic targets in the immune system, or as
checkpoints exploited by the tumor.
Tak Mak (Princess Margaret Hospital, Toronto) sum-
marized the impact of nutrient and metabolic stress in
the tumor micro-environment. Tumor cells and tumor-
infiltrating immune cells are competing for the samelimited resources (including glucose, oxygen, reducing
thiols and amino acids), and experience the same environ-
mental metabolic stresses (free radical flux, hypoxia, etc.).
Thus, pathways that sense and respond to nutrient-related
stress are important for both tumor biology and for local
immune responses: examples include mTOR, ER stress
(e.g., PERK), autophagy, GCN2, HIF-1α and redox path-
ways. Glycolysis is important for tumor cells (Warburg
effect), and glycolysis is also required for activation of
effector T cells. In contrast naive T cells and Tregs may
preferentially use fatty-acid metabolism. Thus, regulatory
pathways such as mTOR that link glycolysis, energy-
balance and redox regulation are important for immune
function in the tumor microenvironment.
David Munn (Georgia Regents University) discussed the
role of metabolic stress as an immunologic checkpoint in
T cells, with a focus on amino acid withdrawal. T cells are
sensitive to amino-acid deprivation during activation.
Either tryptophan depletion (via IDO expressed in DCs
or macrophages), or arginine depletion (via Arginase I
expressed in macrophages or MDSCs), can activate the
amino-acid sensitive GCN2 pathway. The result is GCN2-
mediated cell-cycle arrest and anergy in effector T cells;
and GCN2-mediated activation in Tregs. mTOR is also
potentially a sensor of amino-acid withdrawal stress,
although a specific role for mTOR in this regard has not
yet been demonstrated. In mouse tumor models, inhibition
of IDO with 1-methyl-D-tryptophan (indoximod) or the
high-affinity IDO-inhibitor NLG919 (NewLink Genetics)
reduced Treg-mediated suppression, and enhanced anti-
tumor responses. Blockade of IDO was synergistic with
blockade of the PD-1/PD-ligand pathway. IDO and PD-L1
are both inducible in the tumor microenvironment by T
cell-driven inflammation, as recently reported by Gajewski
and colleagues [19], so these pathways may function as
inducible counter-regulatory mechanisms to limit anti-
tumor immune responses.
Madhusudhanan Sukumar (National Institutes of Health)
described the role of mitochondrial metabolism in regulat-
ing CD8+ T cell memory and self-renewal. Activated T
cells must convert large quantities of nutrients to energy.
Different subsets of T cells, and different stages of dif-
ferentiation, have differing requirements for glycolysis and
mitochondrial metabolism. When CD8+ T cells undergo
activation and effector differentiation, they become heavily
dependent on the glycolytic pathway. Inhibition of gly-
colysis during activation favors formation of long-lived
memory cells, rather than terminal differentiation into
short-lived effector cells. Identification and isolation of
cells with lower mitochondrial membrane potential (by
use of a fluorescent marker dye) allowed enrichment of
CD8+ T cells with a more “stem-like” gene-expression pro-
file. Following adoptive transfer, these cells mediated
enhanced anti-tumor activity and markedly increased
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quent reduced free-radical flux, may help protect long-
lived cells from free-radical damage and early senescence.
Paolo Rodriguez (Louisiana State University) described
therapeutic modulation of T cell function via arginine
metabolism. T cells are sensitive to arginine deprivation,
which activates the GCN2 kinase pathway, leading to cell-
cycle arrest and anergy. Dr. Rodriguez and colleagues have
developed a PEG-conjugated form of recombinant human
L-arginine (peg-Arg I). In vitro, treatment with peg-Arg I
did not affect early activation events in resting T cells, but
it inhibited subsequent cell cycle progression and effector
differentiation. In vivo, administration of peg-Arg I cre-
ated systemic arginine depletion and inhibited T cell
activity. Arginine depletion also was associated with an
increase in the number of granulocytic MDSCs in vivo.
When tested in disease models (graft-vs-host disease and
inflammatory bowel disease), peg-Arg I significantly ex-
tended survival of treated mice.
Biomarkers and immunoscore
The advent of novel but high-cost treatments for meta-
static melanoma, such as ipilimumab and anti-PD1 (e.g.
nivolumab), has emphasized the need for biomarkers that
can be used to predict those patients most likely to re-
spond to therapy. For ipilimumab, we know treatment can
improve overall survival but not the surrogate endpoints
of overall response or progression-free survival. In addition,
specific subgroups of patients with a higher benefit have
not been identified. However, as reported at the 2013
European Cancer Congress, about one-fifth of patients
who receive ipilimumab are still alive at 10 years [20].
As such, biomarkers to predict these patients with poten-
tial long-term benefit from ipilimumab therapy would be
very welcome. For anti-PD1 treatment, PD-L1 expression
in the tumor might be expected to be a predictive bio-
marker for response. However, this hypothesis is compli-
cated by that finding that about 20% of patients who are
PD-L1 negative respond to anti-PD1 treatment (see “Hot
Topic” summary, below). Finally, there is increased inter-
est in the correlation between the presence of immune
infiltrate in the tumor microenvironment and patient out-
comes. This infiltrate might predict not only the prognosis
(as evidenced for the immunoscore in colorectal cancer
but also response to treatment, including chemotherapy
as well as immunotherapy [21]. In fact, in a recent pub-
lished adjuvant trial of patients with breast cancer, the
presence of the immune infiltrate correlated with a better
outcome only in the triple-negative patients. In the HER2-
positive population, the presence of infiltrate was asso-
ciated with a better outcome in patients treated with
doxorubicin-based chemotherapy but not in patients receiv-
ing docetaxel in addition to doxorubicin-based treatment,
suggesting that somehow the addition of the docetaxelmight have interfered with some immune-based anti-tumor
mechanism in this setting [22].
Mohammed Kashani-Sabet (University of California,
San Francisco, CA, USA) and colleagues have found that
the Pleckstrin homology domain-interacting protein (PHIP)
is a marker and mediator of melanoma metastasis. Over-
expression of PHIP is an independent adverse predictor
of survival in melanoma patients and a high proportion
of melanomas have been reported to harbor an increased
PHIP copy number. PHIP-overexpressing tumors include
triple-negative (wild-type BRAF, NRAS, and PTEN) and
double-negative melanomas (mutant BRAF and wild-
type NRAS and PTEN). In 238 patients with melanoma,
PHIP copy number was independently predictive of distant
metastasis-free survival (p = 0.03) and disease-specific sur-
vival (p = 0.03) [23]. Increased PHIP copy number was also
predictive of ulceration (p = 0.04). PHIP overexpression
may lead to increased glycolytic activity, with lower expres-
sion of lactate dehydrogenase (LDH)-5, hypoxia-inducible
factor-1α subunit, and vascular endothelial growth factor,
as well as increased micro-vessel density. Increased gly-
colysis and angiogenesis may be drivers of ulceration and
metastasis.
The role of a 12-chemokine gene signature as a marker
in the selection of patients for immunotherapy was re-
ported by James J. Mulè (Moffitt Cancer Center, Tampa,
FL, USA). This 12-chemokine gene signature predicts the
presence of unique, ectopic lymph node-like structures
in solid tumors, including metastatic melanomas. A dir-
ect correlation between the 12-chemokine gene signa-
ture score and the presence of these structures was
associated with better overall survival in a small group
of melanoma patients [24]. It has been postulated that
chemokines produced locally within the microenviron-
ment of the tumor are responsible for the formation of
these lymph node-like structures, which may play an im-
portant role in eliciting an endogenous anti-tumor immune
response, thereby improving patient outcomes. The use of
this 12-chemokine gene signature may reveal information
on the anti-tumor immune response, potentially leading to
improvements in the identification and selection of melan-
oma patients most likely to respond to immunotherapy.
Margaret K. Callahan (Memorial Sloan-Kettering Cancer
Center, New York, NY, USA) reported information on
biomarkers from two phase I studies in patients with
advanced melanoma treated with the anti-PD1 agent nivo-
lumab alone (trial CA209-003) and in combination with
ipilimumab (trial CA209-004). Rapid and durable responses
were observed for both nivolumab monotherapy and
ipilimumab plus nivolumab combination therapy; these
responses persisted after discontinuation of treatment
in some patients. Positive PD-L1 staining of pretreat-
ment tumors suggested an increased likelihood of re-
sponse to nivolumab monotherapy but not ipilimumab
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ports with ipilimumab monotherapy [25,26], baseline ab-
solute lymphocyte count (ALC) did not predict response
to either nivolumab monotherapy or combination therapy.
In patients receiving combination therapy, increased num-
bers of CD4+ and CD8+ T cells expressing activation and
proliferation markers were observed while a higher overall
response rate correlated with low pre-treatment levels of
myeloid-derived suppressor cells (MDSC) in an explora-
tory single-center subset analysis.
A specific 53-gene panel predictive of non-progression
and prolonged survival in two independent cohorts of
patients with resectable stage II-III melanoma was
identified by Yvonne Saenger using a hypothesis-driven
approach (Mount Sinai School of Medicine, New York,
NY, USA) and co-workers. These 53 genes have high
overlap with a co-expression network identified using
unbiased methods using National Center for Biotech-
nology Information (NCBI) Gene Expression Omnibus
(GEO) data. Bayesian network analysis was used to de-
fine gene networks surrounding the 53 genes, with key
hub genes within defined immune signaling pathways
identified as potential key regulators. Th1 processes, T and
B cell receptor activation, and CD2 were identified as crit-
ical modulatory pathways. CD2 staining by immunohis-
tochemistry was also predictive of non-progression and
prolonged survival. The 53-gene panel should be prospect-
ively studied in larger trials, while nodes in the Bayesian
network could represent potential therapeutic targets.
Combination approaches in cancer
Historically, neoplastic disease represents a clear example
of the importance of combined treatment strategies. In
fact, combinations of surgery, radiotherapy and/or chemo-
therapy have typically represented the best approach for
the treatment of various tumors, such as breast, ovarian
and head and neck cancer. The development of new com-
pounds, in particular immunomodulatory antibodies and
targeted therapies, provide the basis for new combination
approaches in the treatment of cancer. The combining,
either concurrently or sequentially, of such compounds
offers the potential for improved outcomes. Combining
these new agents with surgery, radiotherapy and/or chemo-
therapy may also provide further opportunities in the man-
agement of cancer.
Mario Sznol (Yale University School of Medicine, New
Haven, CT, USA) discussed various combinations of anti-
cancer immunotherapies based on checkpoint inhibition,
in particular a combination of nivolumab plus ipilimumab
in a 1:3 dose ratio that was associated with a 53% con-
firmed objective response rate (three complete and six par-
tial responses) in patients with advanced melanoma [27].
However, there are many unresolved issues regarding dos-
ing and sequencing of combination treatments, e.g. theeffects of varying dose ratio on toxicity, whether to use
concurrent or sequential therapy, and the possible add-
itional activity of single-agent use after combination ther-
apy. Moreover, optimal management of patients will be
complex and will not follow clean protocol-related rules.
There must also be an acceptance of increased frequency
and severity of adverse events accompanying greater activ-
ity. Clinical trial endpoints may also shift from median sur-
vival to overall cure rates.
More biomarker data were presented by Laurence
Zitvogel (Institute Gustave Roussy, Villejuif, France). Effi-
cacy of ipilimumab was reduced by interleukin (IL)-2Rβ
(CD122), IL-2 or IL-15 blockade in mice inoculated with
MCA205OVA or MC38OVAdim tumor cell lines. More-
over, high levels of soluble IL-2 receptor α (sCD25), com-
bined with high LDH-5 levels, predicted resistance to
ipilimumab. In 262 patients with metastatic melanoma,
high sCD25 was associated with worse survival compared
with low sCD25. Soluble CD25 is thought to act as a
decoy receptor with immunosuppressive functions. An as-
sessment of biomarkers for response to the engineered
anti-PD-L1 antibody MPDL3280A was also reported. In a
phase I study in non-small-cell lung cancer, the best over-
all response rate to PD-L1 blockade was seen in patients
with more than 10% tumor immune cells positive for
PD-L1. These findings are consistent with the data that
pre-treatment PD-L1 expression suggests increased likeli-
hood of response to nivolumab monotherapy.
Stefani Spranger (University of Chicago, Chicago, IL,
USA) described how the improved therapeutic efficacy
of combination immunotherapy may be associated with
re-activation of T cells directly within the tumor micro-
environment. In mice inoculated with B16-SIY tumor cells,
tumor control was increased by combined therapy consist-
ing of blockade of CTLA-4 and PD-L1, CTLA-4 and
indoleamine-2,3-dioxygenase (IDO) or PD-LI plus IDO
versus respective monotherapies. Early T cell priming was
only minimally affected by combination immunother-
apies. However, immunotherapy combinations increased
the number of CD8+ tumor-infiltrating lymphocytes (TILs)
that proliferated and produced IL-2. Combinations also in-
creased the percentage of BrdU +T cells in the tumor.
Altogether, the data indicate that re-activation of tumor
residing T cells mediated tumor control after combination
therapy. Further the combination of CTLA-4 and PD-L1
blockade delays tumor outgrowth in subsets of genetically-
induced melanoma models, with the anti-tumor effect
linked to a pre-existing T cell infiltrate. Thus, cancer
immunotherapy approaches targeting negative regulatory
immune checkpoints might be preferentially beneficial for
patients with a pre-existing T cell-inflamed tumor micro-
environment, with IL-2 production and proliferation of
CD8+ TIL potential biomarkers to be investigated in regard
to clinical response to immunotherapy. Other potential
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3, 4-1BB, and OX-40, should also be integrated into com-
bination therapy studies.
A novel combination of three immunostimulatory mono-
clonal antibodies (anti-CD137, anti-OX40 and anti-PD1)
was investigated by Aizea Morales-Kastresana (Center for
Applied Medical Research [CIMA], University of Navarra,
Pamploma, Spain) and colleagues using a transgenic mouse
model of multifocal and rapidly progressing hepatocellular
carcinoma. The combination extended survival of mice
in a CD8-dependent fashion and synergized with adop-
tive T cell therapy using activated OVA-specific TCR-
transgenic OT-1 and OT-2 lymphocytes. There was an
increase in CD3+ lymphocyte infiltrates in tumor nodules,
but not healthy liver tissue. CD8+ TILs were more blastic
and showed higher expression of treatment targets, allow-
ing the readministration of the combination. The triple
combination also prevented tolerization of transferred
activated OT-1 T cells against the well characterized CD8+
T cell epitope SIINFEKL. TILs from combination-treated
mice recognized unknown epitopes on hepatocellular
carcinoma-derived cell lines, but not SIINFEKL.
Combination therapies of engineered oncolytic viruses
and immunomodulatory antibodies present an attractive
therapeutic strategy for clinical exploration in different
tumor types. Dmitriy Zamarin (Memorial Sloan-Kettering
Cancer Center, New York, NY, USA) reported the use of
Newcastle disease virus (NDV), a member of the Para-
myxoviridae family, which has been shown to infect a
number of avian species. Naturally-occurring attenuated
NDV viruses have previously been shown to be effective
oncolytic agents against a variety of cancers, including ma-
lignant melanoma. Combination therapy with NDV and
CTLA-4 blockade leads to rejection of injected and distant
B16-F10 tumors and long-term survival in mice. NDV is a
strong inducer of type I interferon through the activation
of TLR7 and RIG-I pathways and upregulates major
histocompatibility complex (MHC) and co-stimulatory
molecules on the surface of tumor cells. Moreover, NDV
induces upregulation of inducible costimulator (ICOS) on
TILs. In combination with anti-CTLA-4, recombinant
NDV expressing ICOS ligand (NDV-ICOSL) results in su-
perior therapeutic efficacy compared with wild-type NDV
in B16-F10 or CT26 murine tumor models. Moreover,
mice cured by combination therapy are protected from
further tumor challenge.
New strategies that target the tumor microenvironment
to promote local and systemic immune protection were
discussed by Yang-Xin Fu (University of Chicago, Chicago,
IL, USA). Evidence suggests that radiation is a significant
modifier of the tumor microenvironment with specific pro-
immunogenic effects that facilitate tumor rejection. Opti-
mal radiotherapy-mediated tumor regression is dependent
on anti-tumor T cells with CD8+ T cell depletion reducingtherapeutic response to radiotherapy. Moreover, an in-
crease in PD-L1 induces tumor resistance and allows re-
lapse in murine cancer models. Radiation combined with
anti-PD-L1 reduces MDSCs through infiltration of cyto-
toxic T lymphocytes (CTLs) in mice. It is hypothesized
that radiotherapy-induced DNA damage leads to excessive
DNA fragments, similar to viral infection, which triggers
interferon (IFN) release to induce dendritic cell matur-
ation and cross-priming. Similarly, the prevention or slow-
ing of HER2/neu + tumor growth by the anti-HER2/neu
antibody also involves an adaptive immune response. This
appears to involve the induction of type I IFNs, with IFNs
not being induced in antibody-resistant tumors; in these
cases, anti-EGFR antibody armed with IFNβ is effective.
Anti-EGFR-IFNβ may induce an anti-tumor cytotoxic T
cell-mediated response through an increase of cross-
priming. Anti-Her2/neu has also been shown to syner-
gize with IL-21 to rapidly eradicate tumors in mice, with
IL-21 amplifying the tumor-specific CD8+ T cell response
through polarized tumor-associated macrophages. Local
irradiation has also been shown to synergize with IL-21.
Hot topic: is PD-L1 tumor expression necessary?
This years “hot topic” session was stimulated by the re-
cent clinical testing of anti-PD1 mAb, a new “checkpoint
inhibitor”, with recent clinical data showing potent activity
in patients with refractory melanoma, renal cell cancer as
well as non-small cell lung cancer. The controversial issue
addressed in this session pertains to the potential need for
PD-L1 (the ligand for the PD1 programmed death recep-
tor) to be expressed on a patient’s tumor in order for that
tumor to respond to anti-PD1 therapy. Drs. Janis Taube
(from Johns Hopkins), Joe Grosso [from Bristol-Myer-
Squibb, (BMS)], and Prim Hegde (from Genentech) each
presented slightly different assays that are being used to
evaluate clinical specimens for the expression of PD-L1
[28]. These different methods have been used to evaluate
separate cancer specimens from patients in distinct clin-
ical trials. For the most part, in clinical testing of single
agent blockade using anti-PD1, patients that have tumors
that show any clear cut expression of PD-L1 are more
likely to respond than patients whose tumors are clearly
negative for PD-L1. In the study using the John Hopkins
monitoring method, no patients that were PD-L1-negative
responded to therapy. In contrast in studies using the BMS
or Genetech assays, patients that were PD-L1-negative
were less likely to respond than those that were PD-L1+,
but approximately 20% still did respond. The differences
seen in these studies might reflect differences in the clinical
trials themselves, as well as potential differences in the sen-
sitivity and scoring criteria, to determine PD-L1 positivity
vs. negativity. If PD-L1 expression is actually a prerequisite
for response to anti-PD1 treatment, then detecting it on a
patient’s tumor might be a reasonable eligibility criterion
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treatment samples is not essential for a response to treat-
ment, PD-L1 testing would not be indicated as a treatment
eligibility criterion. As the clinical results came from 3 dif-
ferent trials, each evaluated using a distinct assay and criter-
ion for determining PD-L1 status, a suggestion was made
to try and resolve this issue. If the samples from all 3 clin-
ical studies could be evaluated for PD-L1 expression, in a
blind fashion, by all 3 detection labs (Johns Hopkins, BMS
and Genentech), it would clarify distinctions in the detec-
tion sensitivity for the 3 separate assays, and provide a
greater sample size of patients with which to correlate the
potential importance of PD-L1 expression in the response
to anti-PD-1 treatment.
Late-breaking abstracts session
Sylvia Adams (NYU Cancer Institute) described the correl-
ation between histologic analysis of lymphocytic infiltration
(a version of the immunoscore) and clinical prognosis in
triple-negative breast cancer. Using a large set of outcome
data available on patients from two adjuvant-chemotherapy
trials (E1199 and E2197), initial biopsy samples were ana-
lyzed morphologically by H&E staining for lymphocyte
infiltration in stroma. The degree of stromal lympho-
cyte infiltration correlated positively with disease-free
survival and overall survival following adjuvant chemother-
apy. Thus, assessment of lymphocytic infiltration provided
additional prognostic information, beyond traditional TNM
staging, in a disease for which additional prognostic mar-
kers are needed.
Antonio Grimaldi (Instituto Nazionale Tumori
Fondazione, Naples) described abscopal responses ob-
served in a group of patients treated with ipilimumab for
metastatic melanoma, who subsequently received local ra-
diotherapy for control of progressive disease. The data were
from a retrospective analysis of 21 patients receiving either
brain or body RT (conventional or stereotactic irradiation)
following progression after ipilimumab (median time after
ipilimumab treatment was 5 months). Abscopal responses,
defined as tumor regression outside of the field of radiation,
were observed in 42% of patients. Patients who had absco-
pal responses had significantly longer overall survival than
patients who did not (22 months vs. 8 months). This report
thus joins a growing body of evidence suggesting that im-
munotherapy such as ipilimumab may “prime” the immune
system to create systemic anti-tumor responses following
local radiotherapy. Conversely, local radiation may trigger
immune responses after immunotherapy that would other-
wise not spontaneously occur (e.g., even in patients who
are actively progressing after immune therapy). It thus
becomes relevant to consider the possibility of planned
addition of local radiation – either sequentially or con-
currently – to ipilimumab therapy, and potentially other
forms of immune-activating therapy.Presidential session
Interventions such as checkpoint blockade, T cell adop-
tive therapy and T cell vaccines are all becoming clinical
realities; but the tumor microenvironment remains a for-
bidding place for T cell function. T cells are often ren-
dered anergic or inhibited in this environment, or they fail
to receive the necessary pro-inflammatory signals from
the innate immune system to support their activation.
Even if they can be successfully pre-activated ex vivo (e.g.,
TILs and CARs) they may not receive the needed signals
to home effectively to the tumor, or they may become sup-
pressed or exhausted when they get there. Thus, strategies
to address these various defects and impediments have be-
come highly topical, and of direct translational interest.
Paolo Rodriguez (Louisiana State University) presented
data elucidating the effects of Notch-1 in T cells. T cells
in the tumor microenvironment are often suppressed or
anergic, and a similar state appears to be induced by
inhibiting Notch signaling in T cells. Dr. Rodriguez and
colleagues showed that Notch-1 and Notch-2 were
elevated during normal T cell activation, and that condi-
tional deletion of Notch-1 and −2 abrogated T cell prolif-
eration and cytokine production. Conversely, transgenic
over-expression in T cells of a constitutively-active Notch-
1 intracellular domain conferred enhanced anti-tumor
effect in vivo, and increased expression of survival re-
ceptors such as IL-7R. Thus, Notch-1/2 signaling in T
cells may act to oppose some of the inhibitory effects of
tumors in vivo. It could thus represent a potential thera-
peutic intervention, or a modification to allow engineered
T cells to be more resistant to the suppressive effects
of tumors.
Seng-Ryong Woo (University of Chicago) presented data
showing that innate immune cells in the tumor micro-
environment sense the presence of growing tumor via the
host STING pathway. STING is an intracellular sensor for
cytosolic DNA, so activation of this pathway in host DCs
requires uptake of tumor DNA. Tracking-dye studies
in mouse models revealed that large numbers of host
DCs acquired tumor-derived DNA. Xenograft models
and other studies suggested that the source of this tumor-
derived DNA appeared to be from tumor mitochondria.
Activation of the STING pathway resulted in local pro-
duction of IFNβ and enhanced T cell priming; conversely,
highly immunogenic tumors were not rejected in STING-
deficient hosts. Thus, innate sensing of tumor-derived
DNA played an important role in priming immune re-
sponses against growing tumors.
Ileana Mauldin (University of Virginia, Charlottesville)
presented preclinical studies describing the effects of TLR-
ligands on chemokine production by human melanoma
cells. Melanoma cell lines expressed multiple Toll-like
receptors, but exposure to their various cognate li-
gands triggered little chemokine production. However, the
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resulted in production of the chemokine CXCL10. Expres-
sion of TLR2 and TLR6 were confirmed on primary hu-
man melanoma samples, as was production of CXCL10 in
response to TLR2/6 ligation plus IFNγ. CXCL10 has been
implicated in T cell recruitment, so this approach could
represent a strategy for enhancing recruitment of T cells
into melanoma lesions.
Cara Haymaker (MD Anderson) presented in vitro and
in vivo data suggesting that expression of the co-inhibitory
receptor BTLA on tumor-infiltrating CD8+ T cells may
confer a survival and functional advantage in vivo. Ligation
of BTLA by its counter-ligand HVEM is inhibitory for
T cell proliferation. However, in clinical trials of TIL
adoptive therapy, patients receiving a higher fraction of
BTLA-expressing cells were found to have improved out-
come. To follow up this seemingly paradoxical observation,
they characterized the BTLA+ and BTLA- CD8+ popula-
tions in the TIL preparations. The BTLA+ cells had a
“younger” (less terminally differentiated) gene-expression
profile; showed higher proliferation and cytokine produc-
tion; and were less susceptible to activation-induced cell
death (AICD). This latter attribute may be related to the
finding that BTLA engagement activated the PI3K-Akt sig-
naling pathway. In vivo tracking of unique CDR3 sequences
in the BTLA+ and BTLA- sub-populations of clinical TIL
preparations showed improved survival and competitive ad-
vantage in vivo in the BTLA+ fraction. Thus, in the context
of highly-activated TIL preparations, the restraining effect




William Merritt (Program Director, Clinical Grants and
Contracts Branch/CTEP, National Cancer Institute) gave
an update on trends and priorities in funding at the NCI,
as well as immunotherapy agents available, and changes in
the Early Clinical Trials program. The slides from the pres-
entation are archived on the SITC website and available for
review. The number of NCI research grants awarded has
been flat since 2011. It is a priority at NCI to maintain
the number of investigator-initiated research grants, and a
number of cuts in other areas have been made to maintain
this level. A list of available CTEP reagents was discussed,
and also a discussion of high-priority targets and agents
for DCTP/CTEP. It was discussed that significant changes
will be made to the NCI Early Clinical Trials Program.
The proposed changes include an expectation for molecu-
lar characterization of the tumor; an expectation that pro-
posals will address some aspect of critical unanswered
questions (whether about the disease itself, biomarkers,
or drug combinations); and a multidisciplinary “team
science” approach will be required. Operational changesto the program will include a more integrated network,
more comprehensive central support (monitoring, data-
capture, PK, etc.), accelerated timeline for approval, and
enhanced funding for molecular characterization and
sample acquisition.
FDA
Raj Puri (Food and Drug Administration) gave an update
on FDA regulatory policy related to cancer immunother-
apy. The slides from the presentation are archived on the
SITC website and available for review. Dr. Puri reviewed
the respective offices within FDA that were responsible for
regulation of different oncology products (small-molecules,
biologics, cellular and gene therapies, vaccines, etc.). Cita-
tions and links were given for several recent “Guidance
for Industry” documents relevant to immunotherapy, in-
cluding guidance on trial design, expanded-access pro-
grams, co-development of agents for use as combinations,
and other areas. Also discussed were “breakthrough ther-
apy” designation; fast-track designation; and accelerated-
approval process. Links were provided to FDA websites,
documents and contact information.
The Cancer Immunotherapy Trials Network (CITN)
The CITN is an NCI-supported consortium, led by PI,
Dr. Martin (Mac) Cheever (Fred Hutchinson Cancer Re-
search Center), that brings together cancer immunolo-
gists from 29 universities and cancer centers in North
America to design and conduct early phase trials for pa-
tients with cancer, to provide the infrastructure essential
for collaboration, and to gain access to top-ranked agents
not broadly available for testing. Since its establishment in
2011, several clinical trials have been formulated, with some
already activated and others nearing activation. These
include clinical trials of IL-15, IL-15/IL15Rα-fusion pro-
tein, anti-PD1, anti-CD40 mAb, IL-7, IDO-inhibitor,
Flt3 ligand. Of the top 11 agents identified in the initial
NCI-Immunotherapy agents 2007 workshops [29], 6 are
in CITN trials, 3 are no longer being manufactured, 1 is
not yet available, and one is not being pursued by CITN.
This record indicates the success of the CITN in its initial
mission, and the importance of making these promising
experimental agents available to the academic research
community, through partnership with the NCI and Indus-
try, as facilitated by this collaborative CITN network.
Conclusion
Certain mAbs and their derivatives can augment ADCC
by specific interactions with molecules expressed on tumor
cell surfaces. For example, in addition to the recently
approved glycoengineered CD20 antibody obinutuzumab,
anti-CD137 enhances the efficacy of tumor-reactive mAbs,
such as rituximab, while anti-GD2 has shown activity in
neuroblastoma when combined with IL-2 and GM-CSF.
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progress over the past year, in particular the preclinical and
clinical development of chimeric antigen receptor modified
T cells (CART). Another area of focus for research has
been to identify biomarkers predictive of response to im-
munotherapy. These include PD-L1 tumor expression for
anti-PD1 therapy, although this association is not yet clear.
High levels of sCD25 combined with high LDH-5 levels
predict resistance to ipilimumab and represent a potential
biomarker for CLTA-4 blockade. Gene signatures may also
represent a feasible approach for selecting patients for
immunotherapy. The importance of biomarkers is also
apparent in the context of various combination therapy
approaches. Combined anti-PD1 and anti-CTLA-4 ther-
apy appears to be promising, as do various other combina-
tions of immunomodulatory mAbs, such as anti-CD137,
anti-LAG-3, anti-4-1BB, anti-OX40), as well as immuno-
therapies combined with vaccines or radiotherapy.
It was clear from this meeting that immunotherapy in-
creasingly offers the potential to improve outcomes for
patients with advanced cancers of a wide variety of types.
Research activity in this field continues to progress and
our understanding of the tumor microenvironment, innate
and adoptive immune responses, the activity of various im-
munotherapeutic modalities, and how to identify patients
most likely to benefit from these treatments, is expanding
at a rapid rate. This increasing momentum should hope-
fully enable immunotherapy to become a recognized
cornerstone of cancer treatment applicable to many more
cancer types and of benefit to many more patients in the
future than was ever possible in the past.
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